A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Myron Stefan Czuczman
Research Funding - Gilead Sciences
Hans Knecht
Research Funding - Gilead Sciences
Rebecca Auer
Research Funding - Gilead Sciences
Joseph James McKendrick
Research Funding - Gilead Sciences
Neil Sun Chua
Research Funding - Gilead Sciences
Kim Linton
Research Funding - Gilead Sciences
Graham Collins
Honoraria - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Leanne Holes
Research Funding - Gilead Sciences
Esteban Abella
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Gilles A. Salles
Research Funding - Gilead Sciences